SCHEMBL4912702

SCHEMBL4912702

O=C(CNc1cc(Cl)ccc1Cl)Nc1ccccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
GRIK1 P39086 3/20 0.58
MEN1 O00255 7/20 0.54
KMT2A Q03164 7/20 0.54
POLB P06746 1/20 0.54
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TRPM4 Q8TD43 1/20 0.53
HDAC1 Q13547 2/20 0.53
DHODH Q02127 1/20 0.52
MAPT P10636 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
GAA P10253 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
ATM Q13315 1/20 0.50
NFKB1 P19838 1/20 0.50
GFER P55789 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8482273 0.88 KMT2A (0.55) RAB9AGRIK1MEN1KMT2APOLB
SCHEMBL4910763 0.86 KMT2A (0.52) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL4911984 0.86 KDM4E (0.60) RAB9ANPC1GRIK1MEN1KMT2A
SCHEMBL4911020 0.85 ALDH1A1 (0.62) RAB9ANPC1GRIK1MEN1KMT2A
SCHEMBL4650557 0.84 KDM4E (0.53) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL4650555 0.83 KDM4E (0.59) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL8478866 0.82 HDAC1 (0.55) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL8693363 0.82 GRIK1 (0.70) GRIK1MEN1KMT2AALDH1A1KDM4E
SCHEMBL7549604 0.82 GRIK1 (0.78) RAB9ANPC1GRIK1MEN1KMT2A
SCHEMBL10501280 0.82 KMT2A (0.68) RAB9ANPC1GRIK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 RAB9A 2260/4885NPC1 1608/4885GRIK1 2747/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 RAB9A 2260/4885NPC1 1608/4885GRIK1 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.